Article

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials-05-01-2002
Volume

Identifying and Documenting Adverse Events at Clinical Study Sites

Columns|View from Brussels

Improving adverse event reporting can lead to improved safety profiles and, consequently, fewer drugs pulled from the market.

External Link - article-20164.pdf

Articles in this issue
Letters to the Editor
Parents for Orphans
Fraud, Abuse, and Consent
Identifying and Documenting Adverse Events at Clinical Study Sites
Brian Koziol
A Model-Based Method for Improving Protocol Quality

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Content
Reaching for the ‘White Spots’ in Rare Disease
August 2nd 2025

Reaching for the ‘White Spots’ in Rare Disease

Peter O'Donnell, ACT's Brussels Correspondent
EU proposal focuses on a subset of underserved rare diseases—exploring the gaps in those conditions for which there is no approved treatment option.
Speeding Up European Clinical Trials in Response to Emergencies
August 2nd 2025

Speeding Up European Clinical Trials in Response to Emergencies

Peter O'Donnell, ACT's Brussels Correspondent
With lessons from COVID now established, concrete ideas on improving drug development strategy for future health threats are beginning to take shape.
European Legislative Proposals Presage New Rules for Clinical Trials
August 2nd 2025

European Legislative Proposals Presage New Rules for Clinical Trials

Peter O'Donnell, ACT's Brussels Correspondent
EU’s sweeping push for major pharma reforms to impact the daily practice of clinical trials community.
Site Logo
August 2nd 2025

Transformations Past and Future for the European Medicines Agency

Peter O'Donnell, ACT's Brussels Correspondent
Dissecting the EMA’s new annual report on milestones reached in clinical research and public health.
Agenda Aims to Recharge UK-Based Clinical Trial Innovation
August 2nd 2025

Agenda Aims to Recharge UK-Based Clinical Trial Innovation

Peter O'Donnell, ACT's Brussels Correspondent
Grading the government’s formal response to reform efforts hopeful of boosting UK’s sagging global standing in drug development.
Site Logo
August 2nd 2025

Europe Enhances Regulatory Support for Tackling Unmet Medical Need

Peter O'Donnell, ACT's Brussels Correspondent
EMA operated-Priority Medicines scheme receives update which will expedite response to applicants.
© 2025 MJH Life Sciences

All rights reserved.